HIV fears as needle exchange to close
The impending closure of the Dunedin-run needle-exchange service could lead to a rise in HIV cases throughout the city, advocates fear.
The Otago Daily Times has been told DISC Trust has lost its contract to administer the programme, which will now be run by Christchurch-based health services provider He Waka Tapu.
The trust, which includes the Southland Harm Reduction Programme, Dunedin Intravenous Organisation, Timaru Needle Exchange Trust and Nelson Injecting Community Health Enterprise, is part of a community network that has run the programme for more than 35 years.
It is understood at least 15 South Island support staff will lose their jobs as a result of the contract's move.
This includes three of the five Dunedin staff.
A Dunedin worker said he was worried about the new provider's lack of experience and "on the ground" knowledge.
In particular, he worried it might stop the peer-based system, in which ex-users, or those who had ties to the community, provided harm reduction advice and support, he said.
"Our biggest concern is the lack of peer input — everyone here in Dunedin is a peer, which greatly reduces the stigmatism of the service.
"Often we're the only point-of-health contact for the intravenous drug users, because of the stigma.
"For intravenous drug users, as soon as they are doing it, they are breaking the law. So everyone that we serve is already on the wrong side of the tracks."
The Dunedin branch also ran a free GP clinic for its clients, and so far, there had been no indication about its future, he said.
"It can take years to build up trust as peers, especially when it comes to getting them accessing the health service."
He Waka Tapu provides personalised health consultations, community health initiatives, mental health crisis intervention, addiction support services, reintegration programmes, family violence prevention and educational offerings to promote holistic wellbeing.
Although He Waka Tapu had "lots of experience in the practical health field", it had no experience in the peer service aspects of the needle-exchange programme, the worker said.
"A huge part of New Zealand's success in not having a widespread HIV problem was down to the provision of clean equipment through the needle-exchange programme.
"For many of our clients, we are the only health-related service that they will see at all.
"A huge part of addiction is a background in trauma — and you would be surprised at how many of our clients' trauma is related to abuse within the healthcare system or setting."
The worker was particularly concerned in the possibility of neglect and logistical issues with setting up a new clean-needle service.
"New Zealand is definitely at risk of another HIV pandemic."
The worker said he had been made aware by Health New Zealand Te Whatu Ora (HNZ) that DISC's contract would wind up in September.
"We only found out yesterday who the new provider is. There's been no contact from the new provider. We can't even imagine how they will staff it without peers."
University of Otago (Wellington) public health department Prof Michael Baker said it would be a "grave step backwards" if the new provider moved away from a peer service.
"It was really best practice internationally because it meant that these groups could maintain the trust of injecting drug users — and that's almost certainly contributed to the long-term success of the programme.
"The HIV response in New Zealand was among the most effective in the world because it had a strong emphasis on basically destigmatising human provision.
"We are a pragmatic society. We want things that work."
HNZ and He Waka Tapu have been approached for comment.
matthew.littlewood@odt.co.nz
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Otago Daily Times
18 hours ago
- Otago Daily Times
HIV fears as needle exchange to close
Contract goes to Chch provider The impending closure of the Dunedin-run needle-exchange service could lead to a rise in HIV cases throughout the city, advocates fear. The Otago Daily Times has been told DISC Trust has lost its contract to administer the programme, which will now be run by Christchurch-based health services provider He Waka Tapu. The trust, which includes the Southland Harm Reduction Programme, Dunedin Intravenous Organisation, Timaru Needle Exchange Trust and Nelson Injecting Community Health Enterprise, is part of a community network that has run the programme for more than 35 years. It is understood at least 15 South Island support staff will lose their jobs as a result of the contract's move. This includes three of the five Dunedin staff. A Dunedin worker said he was worried about the new provider's lack of experience and "on the ground" knowledge. In particular, he worried it might stop the peer-based system, in which ex-users, or those who had ties to the community, provided harm reduction advice and support, he said. "Our biggest concern is the lack of peer input — everyone here in Dunedin is a peer, which greatly reduces the stigmatism of the service. "Often we're the only point-of-health contact for the intravenous drug users, because of the stigma. "For intravenous drug users, as soon as they are doing it, they are breaking the law. So everyone that we serve is already on the wrong side of the tracks." The Dunedin branch also ran a free GP clinic for its clients, and so far, there had been no indication about its future, he said. "It can take years to build up trust as peers, especially when it comes to getting them accessing the health service." He Waka Tapu provides personalised health consultations, community health initiatives, mental health crisis intervention, addiction support services, reintegration programmes, family violence prevention and educational offerings to promote holistic wellbeing. Although He Waka Tapu had "lots of experience in the practical health field", it had no experience in the peer service aspects of the needle-exchange programme, the worker said. "A huge part of New Zealand's success in not having a widespread HIV problem was down to the provision of clean equipment through the needle-exchange programme. "For many of our clients, we are the only health-related service that they will see at all. "A huge part of addiction is a background in trauma — and you would be surprised at how many of our clients' trauma is related to abuse within the healthcare system or setting." The worker was particularly concerned in the possibility of neglect and logistical issues with setting up a new clean-needle service. "New Zealand is definitely at risk of another HIV pandemic." The worker said he had been made aware by Health New Zealand Te Whatu Ora (HNZ) that DISC's contract would wind up in September. "We only found out yesterday who the new provider is. There's been no contact from the new provider. We can't even imagine how they will staff it without peers." University of Otago (Wellington) public health department Prof Michael Baker said it would be a "grave step backwards" if the new provider moved away from a peer service. "It was really best practice internationally because it meant that these groups could maintain the trust of injecting drug users — and that's almost certainly contributed to the long-term success of the programme. "The HIV response in New Zealand was among the most effective in the world because it had a strong emphasis on basically destigmatising human provision. "We are a pragmatic society. We want things that work." HNZ and He Waka Tapu have been approached for comment.
Newsroom
a day ago
- Newsroom
A win-win-win over medical waste
If you've ever sat in a GP's rooms, a hospital emergency department or ward you've probably watched as a doctor or nurse opens a sterile packet of something, uses it once, then bins it. If you had that material at home you'd probably wash it and use it again – items such as deep vein thrombosis sleeves, patient transfer mattresses and blood pressure cuffs. You wouldn't be the only one wondering about the waste. Now, a Kiwi company has an answer, and is taking more than 50 types of single-use medical devices and giving them a second life. Canterbury-based Medsalv reckons it has so far saved more than half a million devices from landfills across Australia and New Zealand, through more than 90 hospitals. It collects the old devices, remanufactures them by inspecting, cleaning, testing and repackaging; and returns them. Along the way it's saving health care providers a lot of money, and creating jobs, many of them for people with barriers to employment. If the whole country got on board, one estimate suggests it could prevent 1700 tonnes of medical waste going to landfills a year and generate $100m in savings. But Medsalv has spent years banging its head against Pharmac's doors, and has only just got onto a secondary list (non-contracted) for approved suppliers, saving hospitals having to go through a procurement process. In the meantime the company's work has been wholeheartedly embraced by Australia, where Medsalv now has a factory with support and funding from the Victorian state government. Medsalv founder and chief executive Oliver Hunt tells The Detail the process to get in the door with Pharmac has been long and exceptionally difficult. After years of discussions, Pharmac has put the Medsalv's remanufactured medical devices on its new comprehensive list, effective from July 1, but it still hasn't made it onto its main contracted list. 'So, we are on a list, but we are not on a contracted list. So, the products that we've put through don't have a price next to them, and the next step for us is to get a contract with whoever the contracting entity becomes. 'I think it's a step in the right direction, and it's good to show people the value of the products that we're delivering, but there are more steps to happen.' Pharmac says having your hospital medical devices in the Hospital Medical Devices List ensures that Health NZ hospitals can consider your products for use in their facility. Health NZ hospitals can choose which devices they buy from the list without needing to run a primary procurement process. Pharmac also told The Detail contracts for medical devices are generally evergreen, meaning they don't have an end date. And this helps to secure the best deals, with a wide range of suppliers. It says the latest comprehensive list brings greater transparency to what's used and funded in public hospitals. But haematologist Dr Ruth Spearing, a supporter of Oliver Hunt and Medsalv, tells The Detail, Pharmac's model is 'completely wrong'. 'I look at the amount of waste that goes to the landfill, the amount of money that is wasted, it is just horrendous. And anything, any company which can reduce that wastage and reduce its expenditure should be being supported and not blocked in the way that Pharmac has consistently blocked Oliver's company. It's such a shame. 'Pharmac's model is completely wrong in so much as it deals with big international device companies and gives them very long contracts and also gives them contracts with fixed amounts so there's no ability of Health New Zealand to actually become more efficient and decrease purchases because those companies have fixed amounts that they have been contracted to sell by Pharmac to Health New Zealand. 'So, the model is completely wrong. And any way to try to break into that model has been seemingly impossible.' Hunt, a mechanical engineer, founded Medsalv while completing his Master's in engineering management at the University of Canterbury. The social enterprise was his Master's project. He says the reprocessing of used single-use devices is meticulous. Every item is collected after use, then cleaned, tested, and sterilised to internationally recognised standards. If anything doesn't pass inspection, it's binned; broken apart into individual materials and recycled where possible. Hunt says the remanufactured devices come back at a lower cost, 'we provide employment for people facing barriers to employment in the process, there's less emissions, less waste… we create some quite significant benefits for the health system and for the hospitals.' He says it's about using innovation to stretch the health dollar. Dr Spearing says New Zealand needs to be 'supporting these companies, we need to be supporting innovation, and we need to be supporting people like Oliver who are making a difference. It really is a win-win-win company.' Check out how to listen to and follow The Detail here. You can also stay up-to-date by liking us on Facebook or following us on Twitter.
Scoop
2 days ago
- Scoop
Experts At The 13th IAS Conference On HIV Science Warn Global HIV Gains At Risk Amid Sudden Funding Cuts
Researchers present predictive modelling and real-world data from Africa and Latin America revealing rising HIV acquisitions, stalled treatment and fragile health systems 8 July 2025 (Kigali, Rwanda) – IAS 2025, the 13th IAS Conference on HIV Science, taking place in Kigali, Rwanda, and virtually from 13 to 17 July, will feature an array of studies that address the current political and financial issues affecting the HIV response, including the implications for Africa and around the world. Recent global funding cuts have fundamentally disrupted the HIV response, threatening life-saving research, prevention and care. Abstracts presented at the conference will give a detailed look at the stark impact of the cuts. They will also show how experts and advocates are working on the ground to confront these new and urgent challenges. 'This year's conference takes place at a paradoxical moment for all of us who have dedicated our careers to ending the HIV pandemic,' IAS President Dr Beatriz Grinsztejn said. 'On the one hand, we're witnessing extraordinary scientific breakthroughs that could transform prevention and treatment and even bring us closer to a cure. On the other hand, these very advances are under threat from massive funding cuts that risk stalling clinical trials, slowing our progress, and jeopardizing the progress we've fought so hard to achieve.' Now, more than ever, it is important for the world to hear directly from HIV researchers, scientists and affected communities. Today's scientific highlights press conference featured four studies that were selected from hundreds of abstracts being presented at IAS 2025. 'The sudden cuts to US funding have been deeply felt across the African continent by the millions of people who rely on HIV prevention, testing and treatment services, and by the researchers and health workers striving to end the pandemic,' IAS President-Elect Prof Kenneth Ngure said. 'The studies discussed at IAS 2025 offer real-world insights into how these actions are impacting vulnerable populations and the impact they could cause in the future.' Modelling of the projected impact on HIV incidence, mortality and PrEP access among key populations in sub-Saharan Africa HIV incidence and related deaths look set to significantly increase in sub-Saharan Africa as a result of funding for PrEP being halted under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), according to a pre-print modelling study, which was presented by lead author Dr Jack Stone, Associate Professor in Infectious Disease Mathematical Modelling at the University of Bristol. PrEP funded by PEPFAR was received by nearly 700,000 people living across 28 sub-Saharan African countries by late 2024. Funding for this medicine was paused in January 2025. The study indicates that this pause could lead to around 6,671 extra HIV acquisitions over a year and 3,617 further acquisitions over the next five years. More than 2,900 of the additional acquisitions are projected to be among gay and bisexual men who have sex with men, while more than 2,000 are shown to be among female sex workers. Findings of the study also estimated increases in HIV acquisition levels will exceed 5% in eight of the 27 countries for men who have sex with men, two countries for people who inject drugs, five countries for trans women and six countries for female sex workers. 'Ceasing PEPFAR's funding for PrEP in sub-Saharan Africa will remove approximately 700,000 individuals from using oral PrEP. If this continued for one year, then 10,000 additional infections could occur over the next five years, with many of these infections being among gay and bisexual men who have sex with men and female sex workers,' Dr Stone said. 'It is crucial that funding is found to continue and expand PrEP services in sub-Saharan Africa.' Session and abstract: Co-Chair's choice: Modelling the impact of cuts in PEPFAR funding for HIV pre-exposure prophylaxis among key populations in sub-Saharan Africa, Oral (6731, Track C) Real-time evidence from Mozambique on how funding cuts have disrupted HIV services and strained national health systems The US funding freeze had an immediate impact on Mozambique, as detailed in the real-world study presented by Anna Grimsrud, Senior Technical Advisor at the International AIDS Society, on behalf of the study team. Mozambique has the third highest number of people living with HIV globally, and health facilities serve approximately 2 million of the 2.4 million people living with HIV. To evaluate the impact of the US executive order on HIV services, the authors compared select indicators from the country's district health information system in February 2024 and February 2025. They found that there was a 25% reduction in ART initiation among adults, from over 22,000 to just over 17,000, in February 2025 compared to February 2024. Among those on treatment, there was a 38% reduction in viral load tests performed. There was also a 37% reduction in test results received and a 33% reduction in the number of results showing viral suppression. Among children, there was a 44% reduction in viral load tests, a 71% reduction in test results received and a 43% reduction in virally suppressed results, indicating a disproportionate impact on the paediatric population. The study projected that, if the funding interruption persists, Mozambique could see an estimated increase of 83,000 new HIV acquisitions (a 15% rise) and 14,000 additional HIV-related deaths (a 10% increase) by the year 2030. Session and abstract: Co-Chair's choice: The impact of the U.S. funding interruption on HIV services and the HIV epidemic in Mozambique, Oral (6810, Track E) On-the-ground report from South Africa showing how funding cuts stalled progress toward ending the HIV pandemic In Johannesburg, South Africa, funding cuts hindered progress made toward ending the HIV epidemic, according to an abstract presented by Khensani Chauke of the Gauteng Provincial Department of Health, Pretoria, South Africa. Johannesburg was the recipient of the Accelerating Program Achievements to Control HIV Epidemic (APACE) award, funded through PEPFAR, to support achievement of the 95-95-95 goals. However, the award was withdrawn in February 2025. This impacted key healthcare workers, including counsellors providing community-based HIV testing to vulnerable populations. The study team assessed the impact of the award termination by comparing HIV tests, HIV diagnoses and ART initiations from 2023 to 2025. They found that testing decreased by 8.5% from Q1 2024 to Q1 2025. There was also a 31% decline in HIV diagnoses and a 30% decline in ART initiations. HIV positivity declined from 3% to 2.2%. Session and abstract: Cascades of HIV prevention, treatment and care: Termination of the USAID APACE award in Johannesburg, South Africa: Impact on the number of people living with HIV tested, diagnosed and initiated on anti-retroviral therapy (ART) (January-March 2023-2025), Poster (6823, Track C) Reports from organizations in 13 Latin American countries on how funding suspensions have impacted the HIV response in that region Meg Stevenson from Johns Hopkins Bloomberg School of Public Health presented data showing how Latin American and Caribbean organizations focused on HIV have been impacted by the suspension of US foreign aid. Researchers distributed an online survey to 40 community-based HIV service organizations in Latin America and the Caribbean between 18 February and 14 March 2025. Funding cuts began in late January. The survey found that 21 of 24 (87%) of participating organizations that reported receipt of US funding in the last year had their funds suspended. These cuts represent an average of nearly 50% of the organizations' annual budgets. In some cases, it was 100% of their budgets. Funding cuts affected programmes that were providing HIV prevention and treatment, as well as ancillary services, to adults and children. Session and abstract: Global and national financing, economic evaluation and sustainability: Impact of US-funding suspensions on HIV response in the Latin America and Caribbean region, Poster (6842, Track E) Call to action for debt refinancing to protect HIV response Zackie Achmat, founder of the Treatment Action Campaign and a member of the Global HIV Treatment Coalition, joined the press conference and shared a call to action on the urgent need for debt refinancing to protect the HIV response in low- and middle-income countries. 'You can't end the AIDS pandemic while African nations must choose between paying creditors and saving lives,' Achmat said. 'As someone who has lived with HIV for more than half my life, I have seen the cost of political inaction. We fought for treatment when the world said it was impossible. Now, the convergence of crushing debt and funding cuts threatens everything we've built. We need urgent debt restructuring so African countries can invest in saving lives instead of servicing debt.' Note: The summaries above are primarily based on submitted abstracts, but in some cases, study teams have provided updated or additional information. Final data presented at the conference may change.
